Evidence map›Paper›PMID 35624737›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Attenuation of Cigarette-Smoke-Induced Oxidative Stress, Senescence, and Inflammation by Berberine-Loaded Liquid Crystalline Nanoparticles: In Vitro Study in 16HBE and RAW264.7 Cells.

Keshav Raj Paudel, Nisha Panth, Bikash Manandhar, Sachin Kumar Singh, Gaurav Gupta, Peter R Wich, Srinivas Nammi, Ronan MacLoughlin, Jon Adams, Majid Ebrahimi Warkiani and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Cigarette smoke components modulate the MR1-MAIT axis.The Journal of experimental medicine · 2025
    Article
  12. Natural Products for the Management of Asthma and COPD.Handbook of experimental pharmacology · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 4 countries.

Keshav Raj PaudelCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2007, Australia.ORCID 0000-0002-3591-2080
Nisha PanthCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2007, Australia.
Bikash ManandharDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.
Sachin Kumar SinghFaculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0003-3823-6572
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, Rajasthan, India.
Peter R WichSchool of Chemical Engineering, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-1522-0340
Srinivas NammiSchool of Science, Western Sydney University, Penrith, NSW 2751, Australia.ORCID 0000-0002-4735-2789
Ronan MacLoughlinIDA Business Park, H91 HE94 Galway, Connacht, Ireland.ORCID 0000-0002-3164-1607
Jon AdamsFaculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, SGR, Malaysia.ORCID 0000-0001-5567-6663
Brian G OliverWoolcock Institute of Medical Research, University of Sydney, Sydney, NSW 2037, Australia.ORCID 0000-0002-7122-9262
Philip M HansbroCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2007, Australia.ORCID 0000-0002-4741-3035
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-7507-1159
University of Technology Sydney · AUIMU University · MYLovely Professional University · INRoyal College of Surgeons in Ireland · IEUNSW Sydney · AUUttaranchal University · INWestern Sydney University · AU

Funding

International Medical University BP I-02/2019(28)Maridulu Budyari Gumal Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) RSEOH CAG PRO21-13876
6 · The paper itself

Abstract

Cigarette smoke is considered a primary risk factor for chronic obstructive pulmonary disease. Numerous toxicants present in cigarette smoke are known to induce oxidative stress and airway inflammation that further exacerbate disease progression. Generally, the broncho-epithelial cells and alveolar macrophages exposed to cigarette smoke release massive amounts of oxidative stress and inflammation mediators. Chronic exposure of cigarette smoke leads to premature senescence of airway epithelial cells. This impairs cellular function and ultimately leads to the progression of chronic lung diseases. Therefore, an ideal therapeutic candidate should prevent disease progression by controlling oxidative stress, inflammation, and senescence during the initial stage of damage. In our study, we explored if berberine (an alkaloid)-loaded liquid crystalline nanoparticles (berberine-LCNs)-based treatment to human broncho-epithelial cells and macrophage inhibits oxidative stress, inflammation, and senescence induced by cigarette-smoke extract. The developed berberine-LCNs were found to have favourable physiochemical parameters, such as high entrapment efficiency and sustained in vitro release. The cellular-assay observations revealed that berberine-LCNs showed potent antioxidant activity by suppressing the generation of reactive oxygen species in both broncho-epithelial cells (16HBE) and macrophages (RAW264.7), and modulating the genes involved in inflammation and oxidative stress. Similarly, in 16HBE cells, berberine-LCNs inhibited the cigarette smoke-induced senescence as revealed by X-gal staining, gene expression of CDKN1A (p21), and immunofluorescent staining of p21. Further in-depth mechanistic investigations into antioxidative, anti-inflammatory, and antisenescence research will diversify the current findings of berberine as a promising therapeutic approach for inflammatory lung diseases caused by cigarette smoking.

Indexed as

airway inflammationberberinecigarette smokingliquid crystalline nanoparticlesoxidative stresssenescence

Identifiers

PMID35624737
PMCPMC9137697
OpenAlexW4225129661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.